Last update Aug. 29, 2021
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Eptifibatide belongs to this group or family:
Main tradenames from several countries containing Eptifibatide in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 0 | % |
Molecular weight | 832 | daltons |
Protein Binding | 25 | % |
VD | 0.18 - 0.26 | l/Kg |
Tmax | 0.1 | hours |
T½ | 2.5 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Hexapeptide that binds to the platelet glycoprotein receptor, inhibiting its aggregation by preventing its binding to fibrinogen and other clotting factors such as von Willebrand factor.
Indicated for the prevention of early myocardial infarction in adults with unstable angina.
Intravenous administration.
At the date of the last update, there was no available published data on its excretion in breast milk.
Its high molecular weight makes it difficult to excrete in breast milk.
Due to its protein nature, it is inactivated in the gastrointestinal tract, not being absorbed (practically nil oral bioavailability), which hinders or prevents the passage into plasma of the infant from ingested breast milk except in the premature and during the immediate neonatal period, during which there may be increased intestinal permeability.